Atara Biotherapeutics moving research division to Thousand Oaks
Atara Biotherapeutics will move its research and development division from Westlake Village to Thousand Oaks, the company said in a news release. The company plans to occupy 91,000 square feet at the yet-to-be-constructed Conejo Spectrum Business Park off of Lawrence Drive and Conejo Spectrum Street. The Sares-Regis Group bought 29 acres of land at the Read More →
Read More →Resonant shipping more than 1 million pre-production parts
Goleta-based radio frequency filter designer Resonant announced Feb. 8 the first shipments of more than 1 million pre-production parts to four manufacturers by a licensee customer, under an agreement established in May of 2016. The agreement covered three high-volume frequency bands called Surface Acoustic Wave duplexers. “Shipping these pre-production parts represents one of the last Read More →
Read More →Bacara Resort & Spa in Goleta put up for sale
The Pacific Hospitality Group listed the Bacara Resort & Spa in Goleta for sale for an undisclosed amount, PHG Chief Investment Officer Kory Kramer said. The Irvine-based company has invested more than $25 million in upgrades and renovations since it purchased the resort in 2013 for an estimated $150 million to $180 million. Improvements included Read More →
Read More →Inphi reports strong fourth quarter revenue growth
Semiconductor producer Inphi, which has operations in Westlake Village, reported fourth quarter net income of $19.1 million, or 42 cents per diluted share, bringing the company to $26.5 million in net income for its fiscal year 2016. Revenues from continuing operations rose 53 percent, from $52.9 million in the fourth quarter of 2015 to $80.9 Read More →
Read More →FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease
The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →
Read More →